These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10528675)

  • 41. Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
    Bernardini K; Lanthaler AJ; Buratti T; Mitterer M
    Am J Hematol; 2006 Mar; 81(3):224-5. PubMed ID: 16493606
    [No Abstract]   [Full Text] [Related]  

  • 42. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes.
    Ariad S; Song E; Cohen R; Bezwoda WR
    Mol Biother; 1992 Sep; 4(3):139-42. PubMed ID: 1445668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Raynaud phenomenon and interferon therapy.
    Creutzig A; Caspary L; Freund M
    Ann Intern Med; 1996 Sep; 125(5):423. PubMed ID: 8702103
    [No Abstract]   [Full Text] [Related]  

  • 44. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
    Berger U; Hehlmann R
    Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
    [No Abstract]   [Full Text] [Related]  

  • 45. Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon-alpha.
    Piette JC; Papo T
    Nephrol Dial Transplant; 1995; 10(9):1781. PubMed ID: 8559510
    [No Abstract]   [Full Text] [Related]  

  • 46. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
    Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
    Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of chronic myeloid leukemia with interferon-alpha].
    Szomor A; Molnár L; Nagy A; Dávid M; Alizadeh H; Kecskés M; Vidra T; Kereskai L; Pajor L; Losonczy H
    Orv Hetil; 2000 Nov; 141(48):2601-4. PubMed ID: 11141958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon-associated retinopathy.
    Savant V; Gillow T
    Eye (Lond); 2003 May; 17(4):534-6. PubMed ID: 12802361
    [No Abstract]   [Full Text] [Related]  

  • 50. Granulomatous bone marrow inflammation during treatment of chronic myeloid leukaemia with interferon alpha-2b.
    Siboni A; Mourits-Andersen T; Moesner J
    J Clin Pathol; 1995 Sep; 48(9):878-80. PubMed ID: 7490329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Major depression and psoriasis activation due to interferon-alpha in a patient with chronic myeloid leukemia; "overlooked and/or misdiagnosed adverse reaction in malignant disease".
    Besisik SK; Kocabey G; Caliskan Y
    Am J Hematol; 2003 Nov; 74(3):224. PubMed ID: 14587060
    [No Abstract]   [Full Text] [Related]  

  • 52. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia.
    Arimura K; Arima N; Ohtsubo H; Matsushita K; Kukita T; Ayukawa T; Kuroki T; Tei C
    Acta Haematol; 2004; 112(4):217-8. PubMed ID: 15564735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The role of alpha-interferon therapy in chronic myeloid leukemia].
    Udvardy M
    Orv Hetil; 2000 Jan; 141(2):67-70. PubMed ID: 10686779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discrepant thyroid function tests in a patient treated with interferon-alpha.
    Chan WB; Chow CC; Cockram CS
    J R Soc Med; 2002 Oct; 95(10):506. PubMed ID: 12356975
    [No Abstract]   [Full Text] [Related]  

  • 55. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon.
    Mahé B; Gaillard F; Labadie F; Papin S; Letortorec S; Moreau P; Harousseau JL; Milpied N
    Leuk Lymphoma; 1995 Nov; 19(5-6):515-7. PubMed ID: 8590856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
    Kantarjian H; Cortes J
    Leukemia; 2004 Mar; 18(3):650. PubMed ID: 14737079
    [No Abstract]   [Full Text] [Related]  

  • 58. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura.
    Sugimoto T; Saigo K; Shin T; Kaneda Y; Manabe N; Narita H; Wakuya J; Imoto S; Murayama T; Matsumoto M; Fujimura Y; Nishimura R; Koizumi T; Kumagai S
    Acta Haematol; 2005; 113(3):198-203. PubMed ID: 15870491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.
    Bremer CT; Lastrapes A; Alper AB; Mudad R
    Am J Clin Oncol; 2003 Jun; 26(3):262-4. PubMed ID: 12796597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.